To promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.

United States115th CongressHR-2212House of Representatives
Updated: Apr 28, 2017

Summary

Creating and Restoring Equal Access To Equivalent Samples Act of 2017 or the CREATES Act of 2017 This bill permits the developer of a drug or biological product to bring a civil action against the license holder of an approved drug or biological product if the holder has declined to make available sufficient quantities of the approved drug or product for the developer's testing.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

  1. Introduced in House

  2. Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    House of Representatives

  3. Referred to the Subcommittee on Health.

    House of Representatives

All available records shown.